指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

成人与造血细胞移植受者的体外膜氧合:国际专家声明

Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement.
指南 / 共识 · Lancet Respir Med · 2023-03-13
一句话结论欧洲重症医学会、体外生命支持组织与国际ECMO网络发布专家共识,为接受造血细胞移植的成人患者是否适合ECMO提供33条强一致、3条弱一致的推荐意见。

该国际专家声明由欧洲重症医学会、体外生命支持组织与国际ECMO网络共同制定,针对接受造血细胞移植(HCT)的成人患者使用体外膜氧合(ECMO)的问题。指导委员会检索ECMO、HCT及免疫效应细胞治疗相关文献,采用Quaker共识法形成意见陈述,国际专家组按RAND/UCLA适宜性方法投票,并遵循AGREE规范撰写。共起草36条陈述,首轮投票后33条获强一致,其余3条经讨论修改后再次投票,最终33条强一致、3条弱一致。该文件可帮助重症医师与血液科医师在HCT成人患者ECMO候选决策中做出判断,并为未来ECMO选择标准与床旁管理研究提供基础。

要点

  • 声明由欧洲重症医学会、体外生命支持组织与国际ECMO网络联合制定,聚焦接受造血细胞移植的成人患者使用ECMO。
  • 共形成36条专家意见陈述,最终33条获强一致、3条获弱一致。
  • 首轮投票后33条即达强一致,剩余3条经指导委员会与专家组全体讨论并改写后再次投票。
  • 该文件旨在指导重症医师与血液科医师在HCT成人患者ECMO候选决策中的困难判断。
  • 声明可为未来聚焦ECMO选择标准与床旁管理的研究提供基础。

适用人群与场景

  • 接受造血细胞移植(HCT)的成人患者,因难治性呼吸衰竭或难治性心衰考虑体外膜氧合(ECMO)时。
  • 声明亦检索了免疫效应细胞治疗相关文献,但适用人群为接受HCT的成人患者。

研究设计与关键结果

  • 制定机构为欧洲重症医学会、体外生命支持组织与国际ECMO网络,采用Quaker共识法形成意见陈述,国际专家组按RAND/UCLA适宜性方法投票,并遵循AGREE规范撰写。
  • 指导委员会共起草36条陈述,首轮投票后33条获强一致。
  • 剩余3条经指导委员会与专家组全体成员讨论并改写后再次投票。
  • 最终33条陈述获强一致、3条获弱一致。

证据类型、等级与局限

  • 证据类型:国际专家共识声明(Position Paper),采用Quaker共识法与RAND/UCLA适宜性方法形成推荐。
  • 推荐强度:33条陈述获强一致,3条陈述获弱一致。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该声明可帮助重症医师与血液科医师在决定接受HCT的成人患者是否适合ECMO时进行决策。
  • 声明可为未来聚焦ECMO选择标准与床旁管理的研究提供基础。

指南或共识出处

  • 《成人与造血细胞移植受者的体外膜氧合:国际专家声明》,欧洲重症医学会、体外生命支持组织与国际ECMO网络,发表于Lancet Respir Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Combined advances in haematopoietic cell transplantation (HCT) and intensive care management have improved the survival of patients with haematological malignancies admitted to the intensive care unit. In cases of refractory respiratory failure or refractory cardiac failure, these advances have led to a renewed interest in advanced life support therapies, such as extracorporeal membrane oxygenation (ECMO), previously considered inappropriate for these patients due to their poor prognosis. Given the scarcity of evidence-based guidelines on the use of ECMO in patients receiving HCT and the need to provide equitable and sustainable access to ECMO, the European Society of Intensive Care Medicine, the Extracorporeal Life Support Organization, and the International ECMO Network aimed to develop an expert consensus statement on the use of ECMO in adult patients receiving HCT. A steering committee with expertise in ECMO and HCT searched the literature for relevant articles on ECMO, HCT, and immune effector cell therapy, and developed opinion statements through discussions following a Quaker-based consensus approach. An international panel of experts was convened to vote on these expert opinion statements following the Research and Development/University of California, Los Angeles Appropriateness Method. The Appraisal of Guidelines for Research and Evaluation statement was followed to prepare this Position Paper. 36 statements were drafted by the steering committee, 33 of which reached strong agreement after the first voting round. The remaining three statements were discussed by all members of the steering committee and expert panel, and rephrased before an additional round of voting. At the conclusion of the process, 33 statements received strong agreement and three weak agreement. This Position Paper could help to guide intensivists and haematologists during the difficult decision-making process regarding ECMO candidacy in adult patients receiving HCT. The statements could also serve as a basis for future research focused on ECMO selection criteria and bedside management.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Di Nardo M, MacLaren G, Schellongowski P, et al. Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement. Lancet Respir Med. 2023. PMID: 36924784. doi:10.1016/S2213-2600(22)00535-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。